Bioscience

Ortho-Clinical Diagnostics licenses Intrinsic Bioprobes’ markers

January 21, 2010

By Flinn Foundation

[Source: GenomeWeb News] – Intrinsic Bioprobes, a private clinical diagnostics developer, said today that it has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, a Johnson & Johnson company.

The blood-circulating proteins covered under the license, which were discovered using Intrinsic’s mass spectrometry-based technology, have been linked with the presence of pre-diabetes and type 2 diabetes, the Tempe, Ariz.-based company said.

For more information: Ortho-Clinical Diagnostics Licenses Intrinsic Bioprobes’ Markers